-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Wells Fargo Downgrades NovoCure to Equal-Weight, Raises Price Target to $107

Benzinga · 01/06/2023 06:19
Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and raises the price target from $89 to $107.